alexa Dynamics of Oxidant-antioxidant System in Patients with Multidrugresistant Tuberculosis Receiving Anti-mycobacterial Therapy | OMICS International
ISSN: 2161-105X
Journal of Pulmonary & Respiratory Medicine

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Dynamics of Oxidant-antioxidant System in Patients with Multidrugresistant Tuberculosis Receiving Anti-mycobacterial Therapy

Dmytro O Butov1*, Michael M KuzhkO2, Irina M Kuznetsova3, Olena O Grinishina4, Olga A Maksimenko5, Tatyana S Butova1 and Irina M Kalmykova6

1Kharkiv National Medical University, Kharkiv, Ukraine

2F.G. Yanovsky National Institute of Phtysiatry & Pulmonology, National Academy of Medical Sciences, Kiev, Ukraine

3Regional TB Hospital image 1, Kharkiv, Ukraine

4Regional TB Dispensary image 3, Zmeyev, Ukraine

5Regional TB Dispensary image4, Izyum, Ukraine

6Regional TB Dispensary image 1, Kharkiv, Ukraine

*Corresponding Author:
Dmytro O Butov
Kharkiv National Medical University
Kharkiv, Ukraine
E-mail: [email protected]

Received date: October 16, 2013; Accepted date: December 17, 2013; Published date: December 19, 2013

Citation: Butov DO, Kuzhko MM, Kuznetsova IM, Grinishina OO, Maksimenko OA, et al. (2013) Dynamics of Oxidant-antioxidant System in Patients with Multidrug-resistant Tuberculosis Receiving Anti-mycobacterial Therapy. J Pulm Respir Med 3:161. doi:10.4172/2161-105X.1000161

Copyright: © 2013 Butov DO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pulmonary & Respiratory Medicine


Tuberculosis; Multidrug-resistant tuberculosis; Relapsed tuberculosis; Newly diagnosed pulmonary tuberculosis; Antituberculosis therapy; Peroxide oxidation of lipids; Antioxidant system


Tuberculosis (TB) remains the global problem of mankind with 8.8 million new cases of TB diagnosed each year and 1.4 million people dying from the disease [1,2]. The emergence of Multi-Drug- Resistant (MDR) and extensively drug-resistant TB threatens disease control efforts throughout the world [3,4]. About 50 million people are estimated to be infected with resistant strains of Mycobacterium tuberculosis [5].

In the last decade the Ukraine experienced marked increase in the proportion of TB strains resistant to one or more anti-mycobacterial drugs, causing reduced effectiveness of standard chemotherapy [6,7]. As a result the frequency of Relapsed or Recurrent Pulmonary Tuberculosis (RPTB) becomes higher [8]. The success of treating relapsed tuberculosis remains low resulting in higher rate of transition to chronic disease and increased mortality [9,10]. One of reasons for relapse include disorders in oxidant-antioxidant system, which affect the proper immune surveillance and exaggerates destructive inflammatory process underlying the variety of pathological changes [11,12]. Several studies have implicated local and systemic intensification of prooxidant- antioxidant system in various forms of pulmonary tuberculosis [13-15].

Clinical manifestations of TB, especially its progression and outcome, are closely associated with nonspecific metabolic perturbations in patients. TB is characterized by the activation of lipid peroxidation (LPO), reduced activity of Antioxidant System (AOS) and other related changes. These processes can play a significant role in elimination of Mycobacterium tuberculosis, but the imbalance in these processes can also causes damage to the healthy lung tissue and enhancement of inflammatory process [16-19].

One of the basic mechanisms that regulate the stability and permeability of cell membranes are LPO and AOS [16,20]. Normally the LPO, i.e., the formation of reactive oxygen species, is counterbalanced by AOS. Our study was aimed to uncover changes of pro-oxidant-antioxidant system in patients with various forms of RPTB, including those with MDR-TB. We have examined the dynamics of oxidant-antioxidant system in TB patients who were receiving antimycobacterial therapy.

Materials and Methods

We have followed 140 patients, aged 20 to 70 years, divided into three groups: the 1st group had 74 patients with MDR-TB; the 2nd group consisted of 66 patients who had pulmonary TB without MDR; and the 3rd group consisted of 30 healthy donors. The 1st group was further divided into two subgroups: 1A, which had 41 patients with RPTB with MDR-TB, 1B – had 33 patients with newly diagnosed pulmonary tuberculosis (NDPTB) with MDR-TB. The 2nd group which had patients without MDR-TB was also divided into subgroups: 2A, consisting of 15 patients with RPTB; 2Bwith 51 patients with NDPTB. All patients had infiltrating pulmonary TB and were receiving standard chemotherapy consisting of daily doses of: isoniazid (0.3 g); rifampicin (0.6 g); pyrazinamide (2.0 g); ethambutol (1.2 g); and/or streptomycin (1.0 g). Patients were recruited at the Regional TB Hospital image 1 and Regional TB Dispensary image 1. both in Kharkiv; Regional TB Dispensary image 3 in Zmeev and Regional TB Dispensary image 4 in Izyum, both in Kharkiv region.

Select parameters of LPO and AOS activities were evaluated by spectrophotometry in serum samples collected between 8 and 9 am prior to treatment initiation and 2 months later. The following parameters of LPO were measured: the content of conjugated Trienoic Fatty Acids (TC) and Lipofuscin Pigments (LP) [21]. The activity of AOS was evaluated by measuring thiol SH-groups [22], Total Antioxidant Activity (TAA) [23], Glutathione Peroxidase (GP) and Glutathione Reductase (GR) [24].

Obtained values were analyzed by the Student t-test. The difference was considered statistically significant at P<0.05 [25].


The patients with pulmonary TB exhibited significant perturbances in LPO and AOS activities as compared to healthy controls. The parameters of pro-oxidant system in TB patients, as shown in Table 1, namely the TC and LP levels, were significantly higher than in healthy donors (p<0.05). The AOS levels, i.e., GP, GR, TAA and SH-groups, as indicated in Table 2, were significant lower than in healthy donors (p<0.05). In general in patients with pulmonary tuberculosis GP and TAA baseline values were almost twice lower and the LP is twice higher than in healthy donors.

Groups and subgroups (n) Trienoic conjugates, mmol/L Lipofuscin pigments, μmol/L
Before Rx After 2 months Before Rx After 2 months
1 (n=74) 12.93 ± 0.25#© 9.05 ± 0.21#©* 1.78 ± 0.05#© 1.2 ± 0.04#©*
1? (n=41) 13.66 ± 0.32©@? 9.59 ± 0.25©*@? 1.92 ± 0.07©@? 1.33 ± 0.05©*@?
1B (n=33) 12.03 ± 0.35©¢® 8.38 ± 0.31©*¢® 1.59 ± 0.07©¢® 1.04 ± 0.04©*¢®
2 (n=66) 10.68 ± 0.24© 7.21 ± 0.21α* 1.41 ± 0.05© 0.97 ± 0.03©*
2? (n=15) 12.08 ± 0.53©? 8.24 ± 0.35©*? 1.63 ± 0.12©? 1.1 ± 0.07©*?
2B (n=51) 10.26 ± 0.24©¤ 6.92 ± 0.24α*¤ 1.34 ± 0.05©¤ 0.94 ± 0.03©*¤
3 (n=30) 7.05 ± 0.22 0.85 ± 0.02

Table 1: Parameters of lipid peroxidation in patients with pulmonary tuberculosis and healthy donors (? ± m).

Groups and subgroups (n) Glutathione peroxidase, s.u. Glutathione reductase, s.u. Total antioxidant activity, % SH-groups, mmol/l
to treatment After two months to treatment after two months to treatment after two months to treatment after two months
1 (n=74) 3.416 ± 0.09295#© 4.562 ± 0.1207#©* 134.7 ± 1.911#© 191 ± 5.150#©* 20.72 ± 0.5031#© 37.93 ± 1.674#©* 3.852 ± 0.1389#© 5.969 ± 0.1706#©*
1? (n=41) 3.139 ± 0.09942©@? 4.216 ± 0.1218©*@? 130.7 ± 2.478©@? 176 ± 5.860©*@? 19.44 ± 0.5037©@? 33.95 ± 1.327©*@? 3.259 ± 0.1587©@? 5.439 ± 0.1888©*@?
1B (n=33) 3.762 ± 0.1488©¢® 4.993 ± 0.2026©*¢® 139.6 ± 2.785©¢® 209.7 ± 7.911 α*¢® 22.30 ± 0.8709©¢® 42.88 ± 3.197©*¢® 4.588 ± 0.1703©¢® 6.627 ± 0.263α*¢®
2 (n=66) 4.128 ± 0.1058© 5.390 ± 0.1280©* 148.6 ± 3.310© 228.7 ± 5.461α* 24.65 ± 0.6289© 51.44 ± 1.838©* 4.883 ± 0.1549© 7.989 ± 0.2162©*
2? (n=15) 3.676 ± 0.1637©? 4.726 ± 0.1624©*? 140.6 ± 3.604©? 206.3 ± 9.687α*? 22.20 ± 1.092©? 39.53 ± 1.502©*? 4.134 ± 0.2883©? 7.073 ± 0.3317α*?
2B (n=51) 4.261 ± 0.1227©¤ 5.585 ± 0.1485©*¤ 150.9 ± 4.109©† 235.2 ± 6.217α*¤ 25.37 ± 0.7222©¤ 54.94 ± 2.102©*¤ 5.103 ± 0.1711©¤ 8.259 ± 0.2513©*¤
3 (n=30) 6.297 ± 0.1985 217.6 ± 5.901 64.73 ± 1.1510 6.66 ± 0.2588

Table 2: Condition indicators antioxidant defense in patients with pulmonary tuberculosis and healthy donors (? ± m).

Two months after treatment initiation with standard chemotherapy a significant reversal in indices of LPO and AOS activities was observed (p<0.05). The levels of TC in LPO system in group 2 and 2B after two months became practically same as in healthy controls (p>0.05) confirming relative recovery of LPO. As for the AOS the recovery was seen in GR and SH- levels other parameters were significantly different (p<0.05) from healthy donors, suggesting the failure to recover after two months. For example levels of SH- in group 2 and 2B were significantly higher than in healthy controls.

The comparison of MDR-TB patients (group 1) with those without MDR-TB (group 2) suggests a significant difference (p<0.05) in terms of reduction of almost all indicators as resulting from 2 months of chemotherapy. A significant difference between groups 1 and 2 was seen between treatment and post-treatment times and the gap was significantly higher in group 1 than in group 2 (p<0.05). The AOS indices were significantly higher in group 2 than in group 1, both prior to treatment and after two months (p<0.05).

The comparison of patients with relapsed and newly diagnosed pulmonary tuberculosis indicates a significant reduction (p<0.05) in all parameters before the treatment and after two months. The indicators of lipid peroxidation were significantly higher in patients with relapsed TB (1A and 2A subgroups) than in patients NDPTB (subgroups 1B and 2B) at both time points (p<0.05). In regard to the AOS significantly lower indices were seen in patients with RTBL (1A and 2A subgroups) than in NDPTB (1B and 2B subgroups) before and after treatment (p<0.05). In addition, in patients with RPTB MDR-TB (subgroup 1A) the values were significantly lower than in RPTB without MDR-TB (subgroup 2A). In patients with NDPTB MDR-TB (subgroup 1B) the values were lower than in subgroup 2B patients, and lipid peroxidation indices in patients with NDPTB without MDR-TB were also lower than in patients 1B subgroup (p <0.05). The indicators of lipid peroxidation in subgroup 1A were significantly higher than in subgroup 2A (p<0.05) at both time points.


We have conducted the measurements of antioxidant enzyme activity and lipid peroxidation parameters in 140 TB patients prior to and after two months on standard TB chemotherapy. In patients with pulmonary tuberculosis marked changes in the prooxidant-antioxidant system were observed as manifested by accumulation in the blood of LPO markers (TC and LP) and decreased function of the antioxidant system. Our data shows more pronounced disturbance in LPO and AOS in patients with relapsed and MDR-TB as compared to those who had newly diagnosed TB or were without MDR-TB. At the end of two months of standard anti-tuberculosis therapy we have observed relative normalization of parameters of LPO and AOS.

Increased activity of lipid peroxidation and decreased performance of AOS in patients with pulmonary tuberculosis provides a rationale to use in addition to standard TB therapy the antioxidant and membrane stabilizing interventions, especially in patients with relapsed MDR-TB.


We thank all volunteers who participated in this study. The wholehearted support of clinicians, nurses and lab personnel who contributed their effort made this study possible. Our gratitude is expressed to many experts in TB and immunology fields who kindly shared with us their opinions and critiques prior to and after this study was completed.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11843
  • [From(publication date):
    December-2013 - Jul 22, 2018]
  • Breakdown by view type
  • HTML page views : 8065
  • PDF downloads : 3778

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version